1. Home
  2. GNS vs MEIP Comparison

GNS vs MEIP Comparison

Compare GNS & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNS
  • MEIP
  • Stock Information
  • Founded
  • GNS 2002
  • MEIP 2000
  • Country
  • GNS Singapore
  • MEIP United States
  • Employees
  • GNS 307
  • MEIP N/A
  • Industry
  • GNS Other Consumer Services
  • MEIP Biotechnology: Pharmaceutical Preparations
  • Sector
  • GNS Real Estate
  • MEIP Health Care
  • Exchange
  • GNS Nasdaq
  • MEIP Nasdaq
  • Market Cap
  • GNS 14.5M
  • MEIP 18.0M
  • IPO Year
  • GNS 2022
  • MEIP 2003
  • Fundamental
  • Price
  • GNS $0.69
  • MEIP $2.52
  • Analyst Decision
  • GNS
  • MEIP Hold
  • Analyst Count
  • GNS 0
  • MEIP 2
  • Target Price
  • GNS N/A
  • MEIP $7.00
  • AVG Volume (30 Days)
  • GNS 5.5M
  • MEIP 19.5K
  • Earning Date
  • GNS 12-24-2024
  • MEIP 02-11-2025
  • Dividend Yield
  • GNS N/A
  • MEIP N/A
  • EPS Growth
  • GNS N/A
  • MEIP N/A
  • EPS
  • GNS N/A
  • MEIP N/A
  • Revenue
  • GNS $23,062,754.00
  • MEIP N/A
  • Revenue This Year
  • GNS $39.87
  • MEIP N/A
  • Revenue Next Year
  • GNS $32.96
  • MEIP $300.00
  • P/E Ratio
  • GNS N/A
  • MEIP N/A
  • Revenue Growth
  • GNS 26.76
  • MEIP 33.76
  • 52 Week Low
  • GNS $0.51
  • MEIP $2.48
  • 52 Week High
  • GNS $9.49
  • MEIP $6.52
  • Technical
  • Relative Strength Index (RSI)
  • GNS 42.21
  • MEIP 29.24
  • Support Level
  • GNS $0.68
  • MEIP $2.65
  • Resistance Level
  • GNS $0.80
  • MEIP $2.89
  • Average True Range (ATR)
  • GNS 0.10
  • MEIP 0.12
  • MACD
  • GNS -0.01
  • MEIP -0.02
  • Stochastic Oscillator
  • GNS 15.70
  • MEIP 8.89

About GNS Genius Group Limited

Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education - entrepreneur education, management consultancy, and business development tools; and Campus - resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment.

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Share on Social Networks: